Management of Abnormal Pap Test Results

Risk-Based Management Framework

The American Society for Colposcopy and Cervical Pathology (ASCCP) recommends using a risk-based framework that combines patient-level risk data with clinical action thresholds to generate personalized management recommendations based on risk for CIN 3 (cervical intraepithelial neoplasia grade 3) 1
This approach identifies high-risk patients who require colposcopy or expedited treatment and low-risk patients who can safely defer invasive diagnostic procedures 1
Electronic tools can facilitate implementation of these guidelines 1

For women aged ≥21 years with ASC-US, the ASCCP recommends three management options: HPV DNA testing (preferred approach), repeat Pap tests at 6 and 12 months, or prompt colposcopy 2
If HPV testing is positive, immediate colposcopy is recommended 2
If HPV testing is negative, repeat testing in 12 months is recommended 2

Colposcopy is recommended for women with LSIL and positive HPV test 4
For women with LSIL who had negative HPV testing or cotest within the previous 5 years, repeat HPV test with or without concurrent Pap test in 1 year is recommended instead of immediate colposcopy 4

Colposcopy or expedited treatment is recommended for women with HSIL 4
For women with HSIL and positive HPV 16, expedited treatment is preferred for non-pregnant patients aged ≥25 years 4

Colposcopy is recommended for all subcategories of AGC 4, 3
Endocervical sampling should be performed during colposcopy 3
Endometrial sampling is recommended in conjunction with colposcopy for women ≥35 years with AGC 3

HPV 16 is the highest-risk HPV type, and for HSIL cytology with HPV 16 positive, expedited treatment should be considered 5
HPV 18 has a high association with adenocarcinoma, and colposcopy is recommended in all cases, even with normal cytology 5

HPV testing or cotesting is preferred to cytology alone for follow-up after abnormal results 5
After treatment for high-grade precancer, surveillance should continue for at least 25 years 5
Initial post-treatment testing includes HPV test or cotest at 6, 18, and 30 months 5

HPV testing should not be used for deciding whether to vaccinate, STD screening, testing patients <21 years, or primary cervical cancer screening as a stand-alone test 6
Clinics should develop protocols to identify women who miss follow-up appointments to ensure they receive needed evaluation and treatment 2
For low-risk findings (e.g., ASC-US or LSIL with recent negative HPV test), immediate colposcopy may represent over-treatment 1